Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653234 | 0.86 | — | — | |
| SCHEMBL12908404 | 0.78 | NCF1 (0.41) | NCF1HRH3CHRM1CHRM2HTR1A | |
| SCHEMBL1158572 | 0.78 | NCF1 (0.41) | NCF1HRH3CHRM1CHRM2HTR1A | |
| SCHEMBL771913 | 0.77 | — | — | |
| SCHEMBL772170 | 0.77 | HRH3 (0.41) | HRH3NPC1CHRM3SMN1; SMN2 | |
| SCHEMBL14076285 | 0.76 | NCF1 (0.50) | NCF1HRH3CHRM1CHRM2HTR1A | |
| SCHEMBL14476814 | 0.76 | NCF1 (0.39) | NCF1HRH3CHRM1CHRM2HTR1A | |
| SCHEMBL25645560 | 0.76 | NCF1 (0.39) | NCF1HRH3CHRM1CHRM2HTR1A | |
| SCHEMBL130689 | 0.76 | — | — | |
| SCHEMBL10694762 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751084-B1 | PYRIMIDINE CARBOXAMIDE DERIVATIVES | EUDIS BIOTECH LLC (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-9249107-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | Maehr, Hubert (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2834223-A2 | (1,2,3-TRIAZOLYL) SULFONYL DERIVATIVES | Apac Pharmaceutical LLC. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-8853248-B2 | (1,2,3-triazolyl)sulfonyl derivatives | MAEHR HUBERT (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2751084-A1 | PYRIMIDINE CARBOXAMIDE DERIVATIVES | Apac Pharmaceutical LLC. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8580805-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130267568-A1 | (1,2,3-Triazolyl)sulfonyl Derivatives | MAEHR HUBERT (US) | 2013-10-10 | — | — | US | disclosed |
| WO-2013151597-A2 | (1,2,3-TRIAZOLYL) SULFONYL DERIVATIVES | APAC PHARMACEUTICAL LLC. (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013032522-A1 | PYRIMIDINE CARBOXAMIDE DERIVATIVES | APAC PHARMACEUTICAL LLC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | MAEHR HUBERT (US) | 2012-03-01 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | NCF1 544/4885HRH3 4130/4885CHRM1 4876/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | NCF1 1154/4885HRH3 3341/4885CHRM1 4851/4885 |
| US-20130267568-A1 | (1,2,3-Triazolyl)sulfonyl Derivatives | IL1B, IL1A, NOD1 | NCF1 162/4885HRH3 2377/4885CHRM1 2725/4885 |
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | NOD1, IL1B, IRAK1 | NCF1 95/4885HRH3 600/4885CHRM1 2280/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | NCF1 544/4885HRH3 4130/4885CHRM1 4876/4885 |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | NOD1, IL1B, IRAK1 | NCF1 95/4885HRH3 600/4885CHRM1 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.